Looking for people with ALS to participate in ADORE trial

The ADORE trial, a large European clinical trial, has recently started at the Beaumont Hospital (Dublin). The aim of this study is to evaluate the efficacy and safety of an oral liquid formulation of edaravone, which was developed by the Spanish pharmaceutical company Ferrer. In some countries outside the EU, edaravone is already prescribed as an intravenous treatment for ALS. The ADORE study is still looking for people with ALS to participate.

If you are interested in participating in this trial, we advise you to discuss this with your neurologist or contact TRICALS via info@tricals.org. TRICALS is an international clinical trial consortium, which collaborates with Ferrer on the ADORE trial.

About ADORE

The ADORE trial is a phase 3 clinical trial that investigates the efficacy and safety of the investigational drug 'FAB122'. FAB122 is an oral liquid formulation of edaravone, a compound that can help prevent oxidative stress. Oxidative stress is the build-up of chemicals that are harmful to cells and tissues, and is thought to contribute to nerve cell death in ALS. Therefore, by decreasing oxidative stress, edaravone could potentially slow ALS progression.

ADORE is a double-blind, randomized, placebo-controlled trial. This means that the effect of FAB122is compared against the effect of a placebo. A placebo is a drug without any active ingredients, a 'dummy drug'. Participants will be randomly assigned to receive FAB122or placebo. Out of every three participants, two will receive FAB122and one will receive the placebo treatment. Neither the participant nor the study team will be told which group the participant has been placed into until after the study has finished.

FAB122and the placebo can be dissolved in water and ingested as a drink. This means that participants can take the investigational drug at home. After the end of the trial, all ADORE participants will be offered the possibility to continue in an open label extension study, in which they will receive daily oral edaravone.

Who can participate?

The main criteria to participate in this trial are:

- You are diagnosed with ALS and between 18 – 80 years of age
- You are within 24 months of symptom onset
- Your lung function is at least 70% at screening visit
- You must not be pregnant or breast-feeding for the entire duration of the study
- If you are using Riluzole you must be on a stable dose for ≥30 days prior to participation and this dose should be maintained during the entire trial.

The trial will run for up to 48 weeks. During this period, you will need to visit the research centre approximately 6 times for examinations. You will be contacted 7 times by telephone in between the visits to the clinic until Week 48.

How can I sign up?

Are you interested in participating? If you fit the above criteria and are living in Ireland, we recommend that you discuss your interest in participation in this trial with your neurologist. You can also contact info@tricals.org for more information and advice.

About TRICALS
TRICALS is a European consortium that is committed to finding better treatments for people with ALS as soon as possible. To this end, TRICALS sets up ALS clinical trials, often together with pharmaceutical companies. These trials are designed to rapidly identify treatment effects. To achieve its goals, TRICALS work closely with people with ALS and ALS foundations. Only together can we turn ALS into a treatable disease and improve quality of life. For more information visit www.tricals.org.

Social media

Twitter	***ADORE trial looking for participants in Ireland!*** The ADORE clinical trial has recently started in the Beaumont Hospital (Dublin) and is evaluating a potential new treatment for people living with #ALS. Are you interested? Read more: [https://www.tricals.org/en/trials/adore-als-trial/]
LinkedIn / Facebook	***ADORE trial looking for participants in Ireland!*** The ADORE trial, a large European clinical trial, has recently started in the Beaumont Hospital (Dublin). The aim of this study is to evaluate the efficacy and safety of an oral liquid formulation of edaravone, which was developed by the Spanish pharmaceutical company Ferrer. In some countries outside the EU, edaravone is already prescribed as an intravenous treatment for ALS. The ADORE trial is still looking for people with ALS to participate. Click on the link for more information about the ADORE trial and how to sign up [l https://www.tricals.org/en/trials/adore-als-trial/] or contact info@tricals.org